Cantor Fitzgerald Maintains Overweight on Taysha Gene Therapies, Raises Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and raises the price target from $2 to $7.
August 14, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Taysha Gene Therapies and raised the price target from $2 to $7.
The raised price target by Cantor Fitzgerald indicates a positive outlook for Taysha Gene Therapies. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100